|CD308||FLT1 (fms-related tyrosine kinase 1), VEGFR1 (vascular epithelial growth factor receptor 1)|
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 1 glycoprotein
|152 / 152|
CD308 is expressed mostly in normal lung, placenta, liver, kidney, heart and brain tissues. Expression is specifically expressed in most vascular endothelium cells, peripheral blood monocytes, osteoblasts and trophoblasts. There is no expression in tumor cell lines.
MOLECULAR FAMILY NAME: Belongs to the tyrosine protein kinase receptor family.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD308|
CD308 binds vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF).
|CD308 is an important mediator of stem cell recruitment and mobilization, angiogenesis and inflammation. CD308 has a tyrosine-kinase activity which is important for the control of cell proliferation and differentiation and plays a role in vascular development and regulation of vascular permeability. |
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD308 IN INTACT ANIMAL
CD308 is a potential target in the treatment of inflammation and atherosclerotic plaque growth. The placental growth factor used CD308 to stimulate angiogenesis and collateral vessel development to bypass atherosclerotic lesions causing ischemia. The anti-CD308 mAb can suppress angiogenesis in tumors and ischemic retinas, in atherosclerotic plaque formation, in inflammation and joint destruction associated with autoimmune arthritis and to reduce mobilization of bone-marrow derived stem cells into peripheral blood and infiltration of CD308 expressing leukocytes into tissues. Ligation of CD308 induces chemotactic migration of mesenchymal progenitor cells and stimulation of osteoblast proliferation suggests CD308 is important in bone formation and remodeling.
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD308: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD308: No information.
Database accession numbers
Revised June 25, 2008